Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CC-Pharming Acquires Rights to Rituxan Biosimilar from Partner iBio

publication date: Aug 28, 2019

CC-Pharming of Beijing acquired an exclusive, royalty-bearing license for China rights to a biosimilar version of Roche's Rituxan (rituximab) developed by iBio of Texas. One year ago, paid $4.7 million to form a joint commercial relationship with iBio giving CC-Pharming the right to use iBio's plant-based technology to develop and manufacture antibodies. At the time, the rituximab biosimilar was expected to be the first antibody developed by the partnership. CC-Pharming intends to use Bio’s FastPharming System for multiple products. More details....

Stock Symbol: (NYSE AMERICAN: IBIO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.